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  27 
Abstract 28 
Objectives 29 
Placental Growth Factor (PlGF) has been shown to be beneficial in diagnosing pre-eclampsia. We performed 30 
a prospective cohort study of revealed PlGF in standard clinical use in four teaching hospitals in UK, 31 
Germany, Austria and Australia. 32 
 33 
Study Design 34 
Clinical data from women with suspected pre-eclampsia or fetal growth restriction < 35 weeks’ gestation 35 
with revealed PlGF measurement were collected (MAPPLE study). 36 
 37 
Main Outcome Measures 38 
Data were compared to the PELICAN study (PlGF concealed). Pre-specified outcomes were compared using 39 
standard statistical tests (median difference or Risk Ratio). The results were further categorised by PlGF 40 
concentration: i) very low (<12pg/ml), ii) low (12-100pg/ml), iii) normal (>100pg/ml). 41 
 42 
Results  43 
396 women managed with revealed PlGF (MAPPLE) were compared with 287 women with concealed PlGF 44 
(PELICAN). Revealed PlGF led to delivery 1.4 weeks earlier (-2.0 to -0.9, 34.9 weeks vs 36.7 weeks). There 45 
were no significant differences in maternal adverse outcomes (11.9% vs 10.1%, Risk Ratio (RR) 1.17, 95%CI 46 
0.76-1.82) or caesarean sections (73.8% vs 64.5%; RR 1.14, 95%CI 1.03 to 1.26).  Revealed PlGF led to fewer 47 
perinatal deaths (2 vs 9; RR 0.16, 95%CI 0.03 to 0.74) and fewer babies with birthweight <3rd centile (28.9% 48 
vs 36.1%; RR 0.80, (0.65 to 0.99), but with more neonatal adverse outcomes (30.4% vs 17.1%; RR 1.78, 95%CI 49 
1.32 to 2.41). 50 
 51 
Conclusions 52 
Revealed PlGF may be associated with lower perinatal mortality and birthweight <3rd centile but appears to 53 
lead to earlier delivery with more neonatal respiratory morbidity. Randomised trials with adequate power 54 
for clinical outcomes are needed.  55 
 56 
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Highlights 64 
 We report PlGF-led management of pregnant women as part of routine clinical care 65 
 We compared our revealed PlGF cohort to a previous cohort with concealed PlGF results 66 
 Revealed PlGF leads to earlier delivery by 1.4 weeks 67 
 Revealed PlGF leads to fewer perinatal deaths and babies <3rd centile at birth 68 
 Revealed PlGF increased neonatal morbidity, predominantly due to respiratory causes 69 
  70 
Introduction 71 
Pre-eclampsia is a multisystem disorder affecting 3-5% of pregnancies and is associated with abnormal 72 
placentation and placental dysfunction (1). The detection of pre-eclampsia is a major focus of maternity care 73 
as it remains a significant cause of maternal and perinatal morbidity and mortality (1). The only treatment 74 
for pre-eclampsia currently available is delivery and therefore accurate diagnosis with the aid of a biomarker 75 
could allow adjustment to clinical care. 76 
 77 
Placental Growth Factor (PlGF) is one of several biomarkers which have been shown to have a predictive 78 
capacity for the screening and detection of pre-eclampsia (2, 3). PlGF is produced by the syncytiotrophoblast 79 
and is identifiable in maternal blood from as early as 12 weeks (4) with concentrations increasing with 80 
gestation until around 30 weeks before declining until birth (5). A decline in PlGF appears to represent a 81 
negative syncytiotrophoblast stress response to a variety of insults ranging from hypoxia (6), inflammation, 82 
oxidative stress(7) and is as such also seen as part of syncytiotrophoblast aging. PlGF concentrations are 83 
lower in pre-eclampsia (2), and extremely low in severe early-onset pre-eclampsia (8). Recently it has also 84 
been suggested that low PlGF concentrations are associated with fetal growth restriction (FGR) (9) and 85 
placental dysfunction (10). 86 
 87 
Currently the National Institute for Health and Care Excellence (NICE) (11) recommends the use of two 88 
platforms for PlGF assessment in pregnancy, produced by Alere (2) and Roche (12). The Alere platform uses 89 
antibodies against PlGF isoform-1, with some cross-reactivity for isoform-2, and has a moderate body of 90 
evidence for its clinical effectiveness at determining pre-eclampsia requiring delivery within 14 days 91 
(PELICAN study) (2, 13). The Roche platform, which measures soluble FMS‑like tyrosine kinase‑1 (sFlt‑1) 92 
relative to PlGF also has a developing body of evidence (PROGNOSIS study) (12). Both tests have been 93 
endorsed by NICE for the investigation of hypertension in pregnancy, to ‘rule out’ a diagnosis of pre-94 
eclampsia (11). Economic benefits, with savings of approximately £500 per patient, have also been 95 
suggested to be achievable if a PlGF based management pathway for women with hypertension in 96 
pregnancy is instigated (13). 97 
 98 
 99 
To date there have not been any published randomised controlled trials of the use of PlGF as a diagnostic 100 
test in women with hypertension in pregnancy. The best estimates of cost-effectiveness and clinical utility 101 
will come from randomised controlled trials such as the PARROT study (14). However, until these are 102 
available comparative cohort studies may offer an insight into the clinical impact of PlGF, when used as a 103 
diagnostic test in women presenting with suspected pre-eclampsia. The objective of the MAPPLE study was 104 
to report clinical outcomes in women managed with revealed PlGF results and to compare those outcomes 105 
with those of the PELICAN study (2) in which clinicians were not informed of the PlGF result. This would 106 
identify the potential clinical implications of revealing PlGF results to the clinician.  107 
 108 
Methods 109 
The Management of pregnancy complications with PIGF testing (MAPPLE) registry was established as a 110 
prospective cohort of women managed with revealed PlGF results according to local guidelines as part of 111 
clinical service evaluation. Four maternity units agreed to compile data on women with pregnancies 112 
complicated by suspected pre-eclampsia or fetal growth restriction managed with revealed PlGF as part of 113 
standard maternity care and funded from within maternity budgets. Participating units were located in the 114 
United Kingdom (Liverpool), Austria (Salzburg), Germany (Osnabrück) and Australia (Adelaide).  115 
A single 2.5ml whole blood sample was taken from each women into bottles containing ethylenediamine 116 
tetra-acetic acid. The plasma derived after centrifugation at 3000rpm for 5 mins was tested for PlGF 117 
concentration, using the Triage system (Alere, San Diego, CA), according to the manufacturer’s instructions. 118 
All meters were programmed throughout to produce a revealed PlGF result available immediately to 119 
laboratory and clinical staff. The assay uses fluorescently labelled recombinant murine monoclonal 120 
antibodies targeted to PlGF, which provide a quantifiable result within the range 12 to 3000pg/mL, within 121 
approximately 15 minutes. The manufacturer states a limit of detection of 9-3000pg/ml (11). 122 
 123 
Women presenting prior to 35 weeks’ gestation attending their local hospital with suspected pre-eclampsia 124 
or fetal growth restriction were offered PlGF testing in line with local hospital policy. No consent was 125 
required as PlGF informed management constituted routine care in these units. Clinicians were aware of the 126 
PlGF result and were expected to adjust care accordingly. An example of the PlGF guideline used at Liverpool 127 
Women’s Hospital can be found in Supplementary Text 1. 128 
 129 
Anonymised clinical data were entered onto a dedicated study case report form. A data transfer agreement 130 
was in place at each site before uploading to a secure database (Simplified Clinical Data Systems, 131 
Portsmouth, NH). The uploaded data were assessed for completeness by the lead author. Ethical permission 132 
was not required as no identifiable patient data were used.  133 
 134 
Data for clinical outcomes were compared, where possible, between revealed (MAPPLE) and concealed 135 
(PELICAN) cohorts (2) using median differences or risk ratios. Only the initial PlGF assessment was used even 136 
if more than one sample was taken to maintain consistency with the PELICAN study.  137 
 138 
The study is essentially a comparison of two cohorts of pregnant women, selected under different 139 
circumstances and for different reasons.  Accordingly, we decided to conduct an unadjusted comparison 140 
between the studies, which reported on all the important measures, and estimated the size of the 141 
differences and then to adjust comparisons for the principal differences between the women prior to PlGF 142 
testing.  Adjustment was made for maternal age, BMI, nulliparity, and proteinuria. For the adjusted analysis, 143 
women with twin pregnancies were excluded, as were women where key predictors were missing.  144 
When comparing event rates (e.g. perinatal deaths, perinatal adverse outcomes, results were expressed as 145 
odds ratios, with 95% confidence intervals. For the main continuous measures birthweight and gestational 146 
age at delivery, differences in the mean were calculated.  For additional measures, either means (with SD) or 147 
medians (with quartiles) were presented. Data are presented in the previously derived ranges of <12pg/ml 148 
(very low), 12-100pg/ml (low; representing <5th percentile of normal) and >100pg/ml (normal) (2, 10). 149 
Birthweights are presented as customised fetal weight centiles (15). We examined whether apparent 150 
differences in infant outcomes could be due to confounding at baseline ( maternal age, singleton pregnancy, 151 
ethnicity, pre-gestational diabetes, APS/SLE, previous pregnancy complications, new hypertension, 152 
suspected FGR and proteinuria) using multiple regression. We also compared the unadjusted and adjusted 153 
impact of revealed PlGF on management of pregnant women (antenatal steroid use, induction of labour, 154 
Caesarean section) using an interaction test.  155 
 156 
Results 157 
Between April 2014 and March 2016, clinical outcomes were obtained from 396 women presenting prior to 158 
35 weeks’ gestation with a known PlGF result and complete outcome dataset. The clinical datasets included 159 
for analysis came from Liverpool: 241 women; Osnabrück: 115 women; Salzburg: 26 women; Adelaide 14 160 
women.  161 
 162 
The MAPPLE cohort varied from the PELICAN cohort in a number of demographic features (maternal age, 163 
twin status, ethnicity, pre-gestational diabetes, APS/SLE, and complications of previous pregnancies) as 164 
shown in Table 1. The distribution of PlGF sub-groups at first sampling were similar.  165 
 166 
There were no significant differences in maternal adverse outcomes between women in the MAPPLE cohort 167 
compared to those in the PELICAN study (11.9% vs 10.1%, Risk Ratio 1.17; 95% confidence intervals 0.76 to 168 
1.82) with the majority of complications related to hepatic and renal dysfunction (Table 2).  169 
 170 
There were 433 babies in the MAPPLE cohort and 299 in PELICAN (Table 2). There was a single stillbirth 171 
within the MAPPLE cohort, in a woman with chronic hypertension with superimposed pre-eclampsia and 172 
severe early-onset FGR who withdrew from clinical care before presenting two weeks later with an 173 
intrauterine fetal death. There were significantly fewer perinatal deaths in the MAPPLE cohort (n=2, 0.5%) 174 
compared to those in the PELICAN study (n=9; 3.0%; Odds Ratio 0.16 (0.03 to 0.74). More babies 175 
experienced a composite perinatal adverse outcome in MAPPLE (n=133, 30.7%) than in PELICAN (n=61; 176 
20.4%; Risk Ratio 1.51 (1.15 to 1.98), Neonatal adverse outcomes were more common in the MAPPLE cohort 177 
(n=131; 30.4% vs. n=51; 17.1%; Risk Ratio 1.78 (1.32 to 2.41); these were dominated by respiratory 178 
morbidity including respiratory distress syndrome (RDS) and bronchopulmonary dysplasia (BPD). A higher 179 
proportion of babies in the MAPPLE cohort were admitted to the neonatal unit compared to those in the 180 
PELICAN study (n=190; 45.5% vs n=117; 39.8%; Risk Ratio 1.14 (0.95 to 1.37). 181 
 182 
The time between first PlGF test and delivery was shorter when PlGF result was revealed to the clinician with 183 
a mean difference of 6 days (-2.0 to -10.0; 24 days vs 29 days) (Table 3). A greater proportion of women with 184 
revealed PlGF (n=236; 59.9%) received antenatal steroids for fetal lung maturation compared to PELICAN 185 
(n=88; 30.1%; Risk Ratio 1.95; 1.61-2.37).  186 
 187 
Fewer women had fetal ultrasound assessment performed after PlGF sampling when PlGF was revealed 188 
(89.1% vs 98.7%; Risk ratio 0.90; 0.87 to 0.94) but the proportion of women with estimated fetal weight 189 
(EFW) <10th centile or abnormal fetal Doppler (absent or reversed end diastolic flow in the umbilical artery) 190 
was similar in both studies. There was no evidence of revealed PlGF testing affecting decisions to give 191 
steroids (p=0.09), induction of labour (0.13) or Caesarean section (0.18) assessed using interaction tests. 192 
Women with revealed PlGF results were delivered at an earlier gestation with a mean difference of 1.4 193 
weeks (-2.0 to -0.9, 34.9 weeks vs 36.7 weeks). There was an increased likelihood of the fetus being 194 
delivered by caesarean section in the MAPPLE cohort compared to the PELICAN cohort (73.8% vs 64.5%: Risk 195 
Ratio 1.14, 1.03 to 1.26). In women managed with revealed PlGF results, there was a significantly lower risk 196 
of women delivering a small for gestational age (SGA) infant <3rd centile (Risk Ratio 0.80; 0.65 to 0.99) 197 
compared to those managed with concealed PlGF results. 198 
 199 
Evaluation of principal outcomes in women with a singleton pregnancy (n=356 in MAPPLE; n=275 in 200 
PELICAN) with adjustment for baseline confounders did not substantially change the findings: mean 201 
gestation at delivery 34.4 (SD 3.6) vs. 36.0 (3.8) weeks; unadjusted median difference -1.33 (-1.89 to -0.77) 202 
and adjusted median difference -0.95 (-1.60 to -0.31) weeks; perinatal adverse outcomes 28.4% vs. 18.9%; 203 
uOR 1.74 (1.20 to 2.51) and aOR 1.51 (0.93 to 2.43). When analysis was restricted to singleton pregnancies, 204 
the increase in Caesarean sections was of borderline significance (uOR 1.39; 1.00 to 1.95) and the odds 205 
reduced (and not significant) when adjusted for baseline confounders between the cohorts (aOR 1.33; 0.85 206 
to 2.07).  207 
 208 
Tables 4 and 5 report maternal and perinatal outcomes for women managed with revealed and concealed 209 
testing by PlGF sub-group (<12, 12-100 and >100pg/ml). A greater proportion of women in the very low PlGF 210 
group in both cohorts had maternal adverse outcomes (compared to the other groups) and the interval from 211 
sampling to delivery was shortest in this group. As these two cohorts are not from a randomised 212 
comparison, and the cohort has been further divided, further statistical testing has not been undertaken.  213 
All stillbirths and perinatal deaths in revealed and concealed cohorts occurred in singleton pregnancies with 214 
abnormal PlGF concentrations (low or very low) (Table 5). Gestation at delivery was earliest in women with 215 
lowest PlGF concentrations, whether the result was revealed or concealed. 216 
 217 
Discussion 218 
In women managed with revealed PlGF results, there were fewer perinatal deaths; this may be due to 219 
modifications in surveillance and monitoring of these pregnancies than if the PlGF result were unknown. 220 
Previous observational cohorts have demonstrated a correlation between low PlGF concentrations at 19-24 221 
weeks’ gestation and subsequent stillbirth (16). Whilst around 25% of fetuses in both cohorts were identified 222 
as having an estimated fetal weight <10th centile on ultrasound at presentation, there were significantly 223 
fewer infants born small for gestational age (<3rd centile) in those managed with revealed PlGF results, even 224 
after adjustment for baseline predictors, suggesting that earlier delivery due to revealed PlGF may have 225 
prevented a slowing of fetal growth in utero. Revealing PlGF was associated with a shorter diagnosis to 226 
delivery interval and an earlier gestation at delivery. We observed a similar rate of antenatal diagnosis of 227 
SGA as the 15% observed in the sFlt1:PlGF study by Zeisler et al. (12). 228 
 229 
The revealing of PLGF to the clinical team was associated with a significant reduction in perinatal mortality. 230 
Not surprisingly this gain comes at the cost of increased neonatal unit admissions and perinatal morbidity, in 231 
particular respiratory complications. This higher prevalence of respiratory morbidity in the MAPPLE cohort 232 
may be related to the earlier gestation at delivery or increased use of caesarean delivery and was not 233 
ameliorated by an increased use of antenatal steroids. Diagnosis of respiratory distress syndrome and 234 
bronchopulmonary dysplasia was similar across centres within the MAPPLE study; it was higher than that in 235 
the PELICAN study and the 10% observed in the TRUFFLE cohort of growth restricted fetuses (who share 236 
many features with women in the PlGF <12pg/ml subgroup) (17).  237 
 238 
Around 10% of women in both cohorts had maternal adverse outcomes, similar to previous observations (2), 239 
with the majority of adverse outcomes other than abnormal biochemistry in women with very low PlGF 240 
concentrations. There was less preeclampsia in the revealed cohort perhaps suggesting that earlier 241 
intervention prevented a worsening of the maternal condition. However, women managed with revealed 242 
PlGF results required frequent attendance at antenatal clinic and admission, possibly due to the persistence 243 
of hypertension and other risk factors. 244 
 245 
This is the largest cohort study to date assessing the impact of PlGF informed care on pregnancy outcome 246 
and provides generalisable ‘real life’ data applicable across healthcare systems. At present these data 247 
provide the best information about the consequences of PlGF results in pregnancy. Outcomes have been 248 
compared between women managed with revealed results (MAPPLE) and those managed with concealed 249 
results (PELICAN) and variation in practice, differences in multiple pregnancy numbers or ethnicity between 250 
different countries could influence some of the outcomes.  Statistical comparison was limited to those least 251 
influenced by possible variations in practice.  252 
 253 
Our findings are  confirmed by the much smaller study by Cetin et al. (18), which assessed just 57 women 254 
with pre-eclampsia and 16 with fetal growth restriction.  255 
 256 
Conclusion 257 
Implication for practice 258 
Our data demonstrate that PlGF-informed management of high-risk pregnancies is feasible within standard 259 
clinical care. This study was not designed to demonstrate cost-effectiveness or perform an economic analysis 260 
of the use of PlGF, but previous assessments have suggested cost savings with PlGF use. Overall, our study 261 
suggests that early intervention with PlGF-led management may prevent worsening of fetal health but at the 262 
expense of earlier delivery and increased neonatal complications, almost exclusively due to respiratory 263 
morbidity, despite increased use of antenatal steroids. This may be offset by lower perinatal mortality and 264 
fewer small for gestational age babies. 265 
 266 
The statistically significant reduction in stillbirths between revealed and concealed PlGF led care is of interest 267 
but there should be caution in interpreting these data in light of the methodological differences between 268 
these two cohorts. Further evidence from randomised controlled trials will assist in interpretation of these 269 
findings. However, studies powered for stillbirth and perinatal death as an outcome are difficult to perform.  270 
The pattern of earlier delivery suggests that clinicians consider optimal management and timing of delivery 271 
in response to the knowledge of PlGF. However, earlier delivery (by six days) was also associated with 272 
worsened short-term neonatal outcomes; this may have been influenced by a lower gestation at enrolment 273 
in the revealed cohort and by the overall earlier gestation at delivery of 1.4 weeks. Education of obstetric 274 
teams and increased confidence in PlGF assessment over time to ensure that PlGF use leads to increased 275 
surveillance rather than precipitating delivery may optimise the benefit (i.e. reduced perinatal death) while 276 
limiting iatrogenic delivery. Likewise, the mode of delivery should be determined by accepted obstetrical 277 
indications rather than PlGF result alone. This should be considered when planning to introduce a new tests 278 
in a high risk population.   279 
 280 
Implications for research 281 
The nature of this study, with different cohorts, precludes more detailed interpretation of the results in table 282 
4 and 5. The true picture of potential clinical benefit or harm from PlGF-led management will only come 283 
from further randomised studies of its use as well as full cost-effectiveness assessment. Until the results of 284 
these studies are available, caution should be exercised before moving to PlGF-led management for all high-285 
risk women. Ongoing and future randomised studies should have adequate power to confirm or refute our 286 
findings. 287 
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  307 
Table 1: Demographic data and clinical characteristics at enrolment for women in MAPPLE (revealed PlGF 308 
testing) and PELICAN (concealed PlGF testing) cohort studies presenting prior to 35 weeks’ gestation. 309 
 310 
 MAPPLE (revealed 
PlGF testing) 
PELICAN (concealed 
PlGF testing) 
Risk Ratio 
 n=396 n=287  
Age (years; median, quartiles) 31 (27-35) 32 (27-36) -1.3 (-0.4 to -2.3) 
BMI (kg/m2; median, quartiles) 27 (24-32) 29 (24-34) -0.8 (-0.1 to -1.8) 
Nulliparous  208 (52.7) 164 (57.1) 0.92 (0.80 to 1.06) 
Singleton pregnancy  360 (90.9) 275 (95.8) 0.95 (0.91 to 0.99) 
Current Smoking  43 (11.3) 24 (8.6) 1.32 (0.82 to 2.12) 
Ethnicity: White 357 (91.1%) 187 (65.6%)  
Ethnicity: Black 12 (3.1%) 70 (24.6%) 0.12 (0.07 to 0.22) 
Ethnicity: Asian 8 (2.0%) 19 (6.7%) 0.24 (0.11 to 0.53) 
Ethnicity: Other 19 (4.8%) 11 (3.8%)  
Previous Medical History    
Previous Preeclampsia 87 (22.0) 55 (19.2) 1.15 (0.85 to 1.55) 
Chronic Hypertension 55 (14.4) 45 (15.7) 0.83 (0.58 to 1.19) 
Systemic Lupus Erythematosus/ 
Antiphospholipid syndrome 
6 (1.5) 12 (4.2) 0.34 (0.13 to 0.89) 
Pre-gestational diabetes 37 (9.3) 6 (2.2) 4.19 (1.79 to 9.79) 
Renal Disease 14 (3.5) 19 (6.6) 0.50 (0.26 to 0.98) 
Previous hypertensive disorder of 
pregnancy (excluding preeclampsia 
7 (1.8) 15 (5.6) 0.32 (0.13 to 0.77) 
    
Indication for PlGF testing (non-exclusive)    
New onset of hypertension 314 (79.5) 155 (54.0) 1.47 (1.31 to 1.66) 
Persistent epigastric/ right upper quadrant 
pain     
12 (3.0) 18 (6.3) 0.48 (0.24 to 0.99) 
Suspected fetal growth restriction 66 (16.7) 25 (8.7) 1.92 (1.24 to 2.96) 
Proteinuria 59 (14.9) 161 (56.1) 0.27 (0.21 to 0.34) 
    
Gestational age at sampling, (weeks; 
median, quartiles) 
30.7 (27.7-33.1) 31.0 (27.9-33.4) -0.1 (0.3 to -0.7) 
PlGF result at first testing     
PlGF <12 117 (29.5) 69 (24.0)  
PlGF 12-100 136 (34.3) 97 (33.8)  
PlGF >100 144 (36.3) 121 (42.2)  
 311 
  312 
Table 2: Maternal and perinatal adverse outcomes for women in MAPPLE (revealed PlGF testing) and 313 
PELICAN (concealed PlGF testing) cohort studies presenting prior to 35 weeks’ gestation with comparisons 314 
for major outcomes. 315 
 MAPPLE (revealed 
PlGF testing)  
PELICAN (concealed 
PlGF testing);  
Risk ratio 
 n=396 n=287  
Final diagnosis of pre-eclampsia (n, %) 193 (52.9) 176 (61.3) 0.86 (0.75 to 0.99) 
Women with maternal adverse outcomes (n, %) 47 (11.9) 29 (10.1) 1.17 (0.76 to 1.82) 
Maternal adverse outcomes (non-exclusive) (n)  55 36 - 
Maternal death 0 0 - 
Central nervous system    
Eclampsia 0 1 - 
Stroke; hypertensive encephalopathy 0 0 - 
Cortical blindness or retinal detachment 0 0 - 
Cardiovascular/ respiratory    
Myocardial infarction 0 0 - 
Intubation (other than for caesarean section) 0 1 - 
Pulmonary oedema 2  2 - 
Haematological    
Platelets <50×10⁹/L (without transfusion) 2 2 - 
Disseminated intravascular coagulation 1 1 - 
Thrombotic thrombocytopenic purpura/ 
haemolytic uraemic syndrome 
0 0 - 
Hepatic    
Dysfunction (Alanine transaminase ≥70IU/L)  38 23  
Haematoma; rupture; acute fatty liver of 
pregnancy 
1 0 - 
Renal    
Creatinine >150 μmol/L 7 2 - 
Dialysis 2 0 - 
Obstetric    
Placental abruption 1 4 - 
    
Number of infants n=433 n=299 Risk Ratio 
Infants with composite perinatal adverse 
outcome (perinatal death or neonatal adverse 
outcome) (n, %) 
131 (30.4) 60 (20.1) 1.51 (1.15 to 1.98) 
Perinatal death (n, %) 2 (0.5) 9 (3.0) 0.16 (0.03 to 0.74) 
Stillbirth (n, %) 1 (0.2) 7 (2.3) - 
Early neonatal death (n, %) 1 (0.2) 2 (0.7) - 
Infants with neonatal adverse outcomes (n, %) 131 (30.4) 51 (17.1) 1.78 (1.32 to 2.41) 
Neonatal adverse outcomes (non-exclusive) (n) 178  62 - 
Respiratory distress syndrome (n) 128 (30.5) 46 (15.4) - 
Bronchopulmonary dysplasia (n) 28 (6.7) 6 (2.0) - 
Intraventricular haemorrhage (Grade 3 or 4) (n) 4 (0.9) 0 (0.0) - 
Necrotising enterocolitis (n) 7 (1.7) 4 (1.3) - 
Retinopathy of prematurity (n) 11 (2.6) 6 (2.0) - 
Infants admitted to neonatal unit (n, %) 190 (45.5) 117 (39.8)  1.14 (0.95 to 1.37) 
 316 
  317 
Table 3: Impact of PLGF testing of the pregnancy management in women in MAPPLE (revealed PlGF 318 
testing) and PELICAN (concealed PlGF testing) cohort studies presenting prior to 35 weeks’ gestation 319 
 MAPPLE (revealed 
PlGF testing) 
PELICAN (concealed 
PlGF testing) 
Median Difference/ 
Risk Ratio 
Maternal  n=397 n=287  
Interval from first test to delivery 
(days; median, quartiles) 
24 (4 to 52) 29 (11 to 59) -6.0 (-2.0 to -10.0) 
Antenatal steroids (n, %) 236 (59.9) 88 (30.7) 1.95 (1.61 to 2.37) 
Induction of labour (n, %) 97 (24.5) 108 (37.6) 0.66 (0.52 to 0.82) 
    
Fetal  n=433 n=299  
Ultrasound scans (n, %) 384 (89.1) 295 (98.7) 0.90 (0.87 to 0.94) 
Estimated fetal weight <10th centile 
(n/N, %) 
80/375 (21.3) 83/285 (29.1) 0.73 (0.56 to 0.96) 
Absent or reduced end diastolic flow 
(umbilical artery Doppler (n/N, %) 
52/384 (13.5) 37/285 (13.1) 1.04 (0.70 to 1.54) 
    
Perinatal n=433 n=299  
Gestational age at delivery (weeks; 
median, quartiles) 
34.9 (32.0-37.1) 36.7 (33.6–38.6) -1.4 (-0.9 to -2.0) 
Caesarean section (n, %) 318 (73.8) 193 (64.5) 1.14 (1.03 to 1.26) 
Birthweight (grams; median, quartiles) 2280 (1490-2960) 2420 (1620–3125) -160 (-15 to -310) 
Small for gestational age infant <10th 
centile (n, %)  
181 (42.2)        145 (48.5) 0.87 (0.74 to 1.02) 
Small for gestational age infant <3rd 
centile (n, %) 
124 (28.9) 108 (36.1) 0.80 (0.65 to 0.99) 
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  321 
Table 4: Maternal and fetal outcomes in women in MAPPLE (revealed PlGF testing) and PELICAN 322 
(concealed PlGF testing) cohort studies presenting prior to 35 weeks’ gestation presented by PlGF results 323 
at enrolment. 324 
 
MAPPLE 
(revealed) 
PELICAN 
(concealed) 
MAPPLE 
(revealed) 
PELICAN 
(concealed) 
MAPPLE 
(revealed) 
PELICAN 
(concealed) 
 PlGF <12 PlGF <12 PlGF 12-100 PlGF 12-100 PlGF >100 PlGF >100 
Maternal  n=116 n=69 n=137 n=97 n=143 n=121 
Final diagnosis of pre-
eclampsia (n, %) 
51 (48.6) 67 (97.1) 69 (53.1) 72 ( 74.2) 73 (56.2) 37 (30.6) 
Women with any maternal 
adverse outcome (n, %) 
25 (21.6) 12 (17.4) 16 (11.7) 8 (8.2)   6 (4.2) 9 (7.4) 
Eclampsia 0 0 0 1 0 0 
Intubation  0 1  0 0 0 0 
Pulmonary oedema 1  2  1 0 0 0 
Platelets <50×10⁹/L  2  1  1 0 0 1 
Disseminated intravascular 
coagulation 
1  1  0 0 0 0 
Dysfunction (Alanine 
transaminase ≥70IU/L)  
23  9  11 7 4 7 
Creatinine >150 μmol/L 1 2 4 0 2 0 
Dialysis 0 0 1 0 1 0 
Placental abruption 1 3 0 0 0 1 
Interval from first test to 
delivery (median, quartiles) 
3 
(1 to 13) 
9  
(3 to 16) 
19 
(6 to 43) 
23  
(11 to 40) 
48 
(32 to 69) 
61  
(37 to 90) 
Antenatal steroids for fetal 
lung maturity (n, %) 
103 (89.6) 41 (59.4) 81 (59.6) 34 (35.1) 52 (36.4) 13 (10.7) 
Induction of labour (n, %) 10 (8.6) 13 (18.8) 35 (25.5) 44 (45.4)  52 (36.4) 51 (42.1)  
Antenatal clinic or 
assessment unit visits 
(mean, SD) 
2.5 (5.5) N/A 3.7 (5.3) N/A 5.2 (5.5) N/A 
Antenatal inpatient nights 
(mean, SD) 
2.3 (4.8) N/A 2.4 (5.8) N/A 3.8 (5.7) N/A 
       
Fetal n=122 n=69 n=158 n=105 n=151 n=125 
Number with ultrasound 
scans (n, %)  
111 (91.0)  68 (98.6) 146 (92.4)  104 (98.4) 127 (84.1)  123 (90.6) 
Estimated fetal weight 
<10th centile (n/N, %) 
50/109 
(45.9) 
43/68 
(63.2) 
17/142 
(12.0) 
28/99  
(28.3) 
13/124 
(10.5) 
12/118 
(10.2) 
Absent or reduced end 
diastolic flow in umbilical 
artery - Doppler (n/N, %) 
36/111 
(32.4) 
24/68 
(35.3) 
12/146  
(8.2) 
9/99  
(9.1) 
4/127 
(3.1) 
4/118  
(3.4) 
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  326 
Table 5: Perinatal outcomes in MAPPLE (revealed PlGF testing) and PELICAN (concealed PlGF testing) 327 
cohort studies presenting prior to 35 weeks’ gestation presented by PlGF results at enrolment. 328 
 MAPPLE 
(revealed) 
PELICAN 
(concealed) 
MAPPLE 
(revealed) 
PELICAN 
(concealed) 
MAPPLE 
(revealed) 
PELICAN 
(concealed) 
 PlGF <12 PlGF <12 PlGF 12-100 PlGF 12-100 PlGF >100 PlGF >100 
Perinatal n=124 n=69 n=158 n=105 n=151 n=125 
Stillbirth (n, %) 1 (0.8) 4 (5.8) 0 3 (2.9) 0 0 
Neonatal death (n, %) 1 (0.8) 2 (2.9) 0 0 0 0 
Gestational age at delivery 
(weeks; median, quartiles) 
31.2 
(29.0-33.4) 
31.9  
(29.3-34.1) 
35.0 
(33.3-36.8) 
35.7 
(34.1-37.9) 
37.4 
(36.1-38.4) 
38.4  
(37–39.9) 
Delivery <37 weeks (n, %) 120 (100) 65 (94.2) 126 (79.7) 64 (60.1) 58 (38.4) 29 (23.2) 
Delivery <34 weeks (n, %) 97 (80.8) 50 (72.5) 48 (30.4) 23 (21.9) 22 (14.6) 10 (8.0) 
Caesarean section (n, %) 115 (94.3) 57 (82.6) 120 (75.9) 74 (70.5) 83 (55.0) 62 (49.6) 
Birthweight (grams; mean, 
SD) 
1360  
(970-1650) 
1280  
(862-1678) 
2290  
(1810-2740)  
2270  
(1757-2830) 
2990  
(2590-3355) 
3100  
(2672-3505) 
Small for gestational age 
infant <10th centile (n, %) 
92 (76.7) 57 (82.6) 65 (41.1) 59 (56.2) 24 (15.9) 29 (23.2) 
Small for gestational age 
infant <3rd centile (n, %) 
71 (59.2) 50 (72.5) 44 (27.8) 46 (43.8) 9 (6.0) 12 (9.6) 
Neonatal unit admission (n, 
%) 
94 (81.7) 53 (82.8) 71 (46.4) 46 (43.8)  25 (16.7) 18 (14.4) 
Infants with neonatal adverse 
outcomes (n, %) 
74 (60.7) 27 (39.1) 37 (23.4) 14 (13.3)  20 (13.2) 10 (8.0) 
Respiratory distress 
syndrome (n, %) 
72 (62.1) 23 (33.3) 36 (23.4) 14 (13.3)  20 (13.3) 9 (7.2) 
Bronchopulmonary dysplasia 
(n, %) 
19 (16.4) 6 (8.7) 4 (2.6) 0 5 (3.3) 0 
Intraventricular haemorrhage 
(Grade 3/4) (n, %) 
2 (1.6) 0 2 (1.3) 0 0 0 
Necrotising enterocolitis (n, 
%) 
4 (3.4) 3 (4.3) 2 (1.3) 0 1 (0.7) 1 (0.8) 
Retinopathy of prematurity 
(n, %) 
7 (6.0) 5 (7.2) 3 (1.9) 1 (1.0) 1 (0.7) 0 
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